CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

NCT00412412 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: CNF2024
DRUG: CNF2024 + trastuzumab

Sponsor

Biogen